A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Systemic scleroderma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FASST
  • Sponsors Inventiva Pharma
  • Most Recent Events

    • 04 Jan 2018 According to an Inventiva Pharma media release, Of the 145 randomized patients 100 patients have been treated for 6 months including 54 patients that have already completed the one year treatment, and topline results are anticipated in early 2019.
    • 04 Jan 2018 According to an Inventiva Pharma media release, Data Safety Monitoring Board (DSMB) has completed its review and recommended to continue this study without any modifications.
    • 22 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top